# Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab

> **NCT00532857** · PHASE2 · COMPLETED · sponsor: **Jungsil Ro** · enrollment: 53 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel/Gemcitabine/Trastuzumab

## Key facts

- **NCT ID:** NCT00532857
- **Lead sponsor:** Jungsil Ro
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-02
- **Final completion:** 2011-09
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2012-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532857, "Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00532857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*